Gibbons, Don L.

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

Gomez, D. R., Blumenschein, G. R., Lee, J. J., Hernandez, M., Ye, R., Camidge, D. R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Gibbons, D. L., et al. (2016) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 1,086

Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer

Sen, T., Rodriguez, B. L., Chen, L., Corte, C. M. D., Morikawa, N., Fujimoto, J., Cristea, S., Nguyen, T., Diao, L., Li, L., et al. (2019) · Cancer Discovery

Cancer Immunotherapy and BiomarkersLung Cancer Research Studies

Cited by 902

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Cascone, T., William, W. N., Weissferdt, A., Leung, C. H., Lin, H. Y., Pataer, A., Godoy, M. C. B., Carter, B. W., Federico, L., Reuben, A., et al. (2021) · Nature Medicine

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 618

CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade

Chen, L., Diao, L., Yang, Y., Yi, X., Rodriguez, B. L., Li, Y., Villalobos, P. A., Cascone, T., Liu, X., Tan, L., et al. (2018) · Cancer Discovery

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 462

Deep learning-based prediction of the T cell receptor–antigen binding specificity

Lu, T., Zhang, Z., Zhu, J., Wang, Y., Jiang, P., Xiao, X., Bernatchez, C., Heymach, J. V., Gibbons, D. L., Wang, J., et al. (2021) · Nature Machine Intelligence

vaccines and immunoinformatics approachesCancer Immunotherapy and Biomarkers

Cited by 295

Smoking, p53 Mutation, and Lung Cancer

Gibbons, D. L., Byers, L. A., & Kurie, J. M. (2014) · Molecular Cancer Research

Cancer-related Molecular PathwaysLung Cancer Research Studies

Cited by 255

Comprehensive T cell repertoire characterization of non-small cell lung cancer

Reuben, A., Zhang, J., Chiou, S.-H., Gittelman, R. M., Li, J., Lee, W.-C., Fujimoto, J., Behrens, C., Liu, X., Wang, F., et al. (2020) · Nature Communications

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 220

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., et al. (2023) · Cancer Discovery

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 203

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Galan-Cobo, A., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., et al. (2024) · Nature

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 194

A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

Nilsson, M. B., Sun, H., Robichaux, J., Pfeifer, M., McDermott, U., Travers, J., Diao, L., Xi, Y., Tong, P., Shen, L., et al. (2020) · Science Translational Medicine

Lung Cancer Treatments and MutationsHippo pathway signaling and YAP/TAZ

Cited by 177

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

Saad, M. B., Hong, L., Aminu, M., Vokes, N. I., Chen, P., Salehjahromi, M., Qin, K., Sujit, S. J., Lu, X., Young, E., et al. (2023) · The Lancet Digital Health

Radiomics and Machine Learning in Medical ImagingCancer Immunotherapy and Biomarkers

Cited by 121

Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy

Soundararajan, R., Fradette, J., Konen, J., Moulder, S., Zhang, X., Gibbons, D., Varadarajan, N., Wistuba, I., Tripathy, D., Bernatchez, C., et al. (2019) · Cancers

Cancer Cells and MetastasisCancer Immunotherapy and Biomarkers

Cited by 103

Dance of The Golgi: Understanding Golgi Dynamics in Cancer Metastasis

Bajaj, R., Warner, A. N., Fradette, J. F., & Gibbons, D. L. (2022) · Cells

Cellular transport and secretionExtracellular vesicles in disease

Cited by 74

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers

Peng, D. H., Rodriguez, B. L., Diao, L., Gaudreau, P.-O., Padhye, A., Konen, J. M., Ochieng, J. K., Class, C. A., Fradette, J. J., Gibson, L., et al. (2021) · Nature Communications

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 72

Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS -Mutant Non–Small Cell Lung Cancer

Araujo, H. A., Pechuan-Jorge, X., Zhou, T., Do, M. T., Hu, X., Rojas Alvarez, F. R., Salvatierra, M. E., Ibarguen, H. P., Lee, R., Raghulan, R., et al. (2024) · Cancer Discovery

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 70

PI4KIIIβ is a therapeutic target in chromosome 1q–amplified lung adenocarcinoma

Tan, X., Banerjee, P., Pham, E. A., Rutaganira, F. U. N., Basu, K., Bota-Rabassedas, N., Guo, H.-F., Grzeskowiak, C. L., Liu, X., Yu, J., et al. (2020) · Science Translational Medicine

Cellular transport and secretionCancer, Lipids, and Metabolism

Cited by 70

ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism

Peng, D. H., Kundu, S. T., Fradette, J. J., Diao, L., Tong, P., Byers, L. A., Wang, J., Canales, J. R., Villalobos, P. A., Mino, B., et al. (2019) · Science Translational Medicine

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 53

A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer

Cascone, T., Sepesi, B., Lin, H. Y., Kalhor, N., Parra, E. R., Jiang, M., Godoy, M. C. B., Zhang, J., Fossella, F. V., Tsao, A. S., et al. (2020) · Clinical Cancer Research

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 31